Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-Mutant and Other HRD+ Cancers

Tango Therapeutics, Inc. announced that the US FDA has cleared the Company’s Investigational New Drug application for TNG348, a novel inhibitor of ubiquitin-specific protease 1 (USP1), for the treatment of BRCA1/2 mutant and other homologous recombination deficient (HRD+) cancers.